| Background: As a common malignant in the world, esophagus cancer has very poor survival rate because of its poor stage when being diagnosed. Concurrent chemoradiotherapy for esophagus cancer has been studied for many years and appears promising result. But the treatment-related toxicity is far higher than radiotherapy alone.Objective: The optional combination of chemotherapeutic agents and radiotherapy dose in concurrent chemoradiotherapy for esophagus cancer remains controversial, especially for advanced patients. In order to reduce the toxicity of concurrent chemoradiotherapy, we conducted the present study which consists of a clinical trial of 2 course of a lower dose of cisplatin(CDDP)/5-Fluorouracil(5-FU) infusion with concurrent radiotherapy in patients with unresectable advanced esophageal cancer.Patients and Methods: Between April 2001 and February 2003, a total of 75 patients with esophagus cancer having T4 tumor or N1 regional lymph node invasion or distant lymph node metastasis(M1a) were enrolled in this study. 5-FU 750mg/d and CDDP 20mg/d was administered on days 1-5 and 22-26.Fractionated radiotherapy was performed from day 1 and total dose of 60Gy-70Gy was delivered at the rate of 2Gy per fraction. The t-test was performed to compare the size of lesions before therapy and that after therapy. Overall survival was estimated by the Kaplan-Meier method.Results: The size of lesions that could be measured in two directions is 10.53 ±...
|
PDF Full Text Request